The dual GIP–GLP-1 receptor agonist tirzepatide that has shown significant benefits in diabetes and obesity may also help prevent diabetic peripheral neuropathy, new research suggests.

New 18-month data for a 10-kHz implanted spinal cord stimulation device (Nevro) shows continued relief of painful diabetic neuropathy symptoms in patients refractory to conventional medical ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

In diabetes, much attention goes to sugar control, insulin levels, and the threat of nerve damage. But a new study reveals ...

The condition, called nonarteritic anterior ischemic optic neuropathy ... compared with 1.8% of those taking other medications for diabetes. Similarly, in the group with obesity, ...

Two independent studies from the University of Southern Denmark (SDU) show that patients with type 2 diabetes who are treated with the drug Ozempic have an increased risk of developing damage to ...

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using semaglutide therapy than when they are not using the drug, according ...

People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. Still, doctors say it shouldn’t deter patients from using the medicines to ...

News. UTD scientists solve 100-year-old mystery behind diabetic nerve damage Nageotte nodules, once overlooked, may hold the key to understanding and treating diabetic peripheral neuropathy.